Genmab — December 2019

[saltpeter]

Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Company Announcement

Genmab and CureVac enter broad strategic partnership
Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research term
Genmab will provide CureVac with a USD 10 million upfront payment and make an equity investment in CureVac of 20 million euro
CureVac eligible to receive milestones between USD 275 million and US

[saltpeter]

368 million for each of the potential product candidates, depending on specific product concept

[bikube]

Mulighed for 50/50 aftale. Mon det bliver noget duobody, der kan blive tale om.

[Helge_LarsenPI-redaktør]

https://ir.genmab.com/news-releases/news-release-details/genmab-and-curevac-enter-strategic-partnership-develop-mrna

[Solsen]

https://www.curevac.com/about-curevac Link til CureVac og interessant læsning

[nohope]

FABELAGTIG AFTALE - for CureVac.

[Solsen]

Jeg tror Genmab har taget rø... på dem

[saltpeter]

Fint,så er der nogen der får glæde af aftalen

[Solsen]

Lad og tage et gns af de to udsagn...

[nohope]

Ja, dejligt der endelig er nogen der får glæde af alle de penge GEN skraber sammen - når nu aktionærerne ikke skal have dem.....

[Solsen]

Har du regnet ud hvad initialinvesteringen koster dig pr aktie ?

[nohope]

Nope - jeg har heller ikke et bud på på hvad det hele kan koste.

[nohope]

Men det ser dyrt ud GEN, GEN betaler hele gildet.

[Solsen]

Mon ikke de har vurderet at det er det værd ?

[nohope]

De sidder forhåbentligvis på info jeg ikke kender. Herunder hvad de egentlig skal forske/udvikle.

[E_L]

we were just recently hinting at more trials in this field - New small trial: Desensitization in Kidney Allograft Using Daratumumab (DARDAR) https://clinicaltrials.gov/ct2/show/NCT04204980?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+Genmab+OR+arzerra+OR+duobody&lupd_s=12%2F18%2F2019&draw=2&rank=2

[E_L]

1 more : Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma - https://clinicaltrials.gov/ct2/show/NCT04205240?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+Genmab+OR+arzerra+OR+duobody&lupd_s=12%2F18%2F2019&draw=2&rank=5

[E_L]

GEN1042 with BioNtech started recruiting https://clinicaltrials.gov/ct2/history/NCT04083599?A=1&B=2&C=merged#StudyPageTop

[DevOp]

CureVac's mRNA platform lyder da ret spændende. Det ser ud til, at de kan bygge mRNA sequences i stabil form. Det burde så både kunne bruges til aktivere immunforsvaret "naturligt" mod cancer celler, få cancercellerne til at udstille flere targets (f.eks. mere CD38) eller at tagge cancer celler med et target, der ikke findes andre steder i kroppen, så bivirkninger mindskes.

[Bulder]

The agreement with biontec is from may 2015. So we must expect 4-5 years from now before anything from the curevac agreement goes into the clinic.